TopoTarget and CuraGen's PXD101 in Ph I trial for solid tumors

13 August 2006

Denmark's TopoTarget AS and USA-based CuraGen say they have initiated a Phase I clinical trial of PXD101 as a treatment for patients with solid tumors. The drug, which is a small-molecule histone deacetylase inhibitor, is also under assessment in a series of Phase II trials as a therapy for blood cancers (Marketletter August 9).

The Phase I solid-tumor study will be an open-label, multicenter assessment of the compound, which is designed to establish its maximum tolerated dose, safety and tolerability.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight